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ABSTRACT
Increasing appreciation of tumor heterogeneity and the tumor-host interaction 
has stimulated interest in developing novel therapies that target both tumor cells and 
tumor microenvironment. Bone marrow derived cells (BMDCs) constitute important 
components of the tumor microenvironment. In this study, we aim to investigate the 
significance of VEGFR1- and VEGFR2-expressing non-tumor cells, including BMDCs, in 
esophageal cancer (EC) progression and in VEGFR1/VEGFR2-targeted therapies. Here 
we report that VEGFR1 or VEGFR2 blockade can significantly attenuate VEGF-induced 
Src and Erk signaling, as well as the proliferation and migration of VEGFR1+ and 
VEGFR2+ bone marrow cells and their pro-invasive effect on cancer cells. Importantly, 
our in vivo data show for the first time that systemic blockade of VEGFR1+ or VEGFR2+ 
non-tumor cells with neutralizing antibodies is sufficient to significantly suppress 
esophageal tumor growth, angiogenesis and metastasis in mice. Moreover, our tissue 
microarray study of human EC clinical specimens showed the clinicopathological 
significance of VEGFR1 and VEGFR2 in EC, which suggest that anti-VEGFR1/VEGFR2 
therapies may be particularly beneficial for patients with aggressive EC. In conclusion, 
this study demonstrates the important contributions of VEGFR1+ and VEGFR2+ non-
tumor cells in esophageal cancer progression, and substantiates the validity of these 
receptors as therapeutic targets for this deadly disease.
INTRODUCTION
Angiogenesis is one of the important hallmarks 
of cancer [1]. It has been more than 40 years since 
Judah Folkman published his classic article “Tumor 
angiogenesis: therapeutic implications” [2], and it is now 
well recognized that vascular endothelial growth factor 
(VEGF), which exerts its functions mainly by binding 
to both VEGF receptor 1 (VEGFR1) and VEGF receptor 
2 (VEGFR2), is the master regulator of the process. 
A number of studies including ours have established the 
clinical significance of VEGF in different types of human 
cancers [3, 4]. In recent years, there is also a growing 
appreciation of the close interaction between cancer cells 
and various elements in the tumor microenvironment, and 
the importance of bone marrow-derived cells (BMDCs) 
as components of the tumor microenvironment that 
contribute significantly to tumor vascularization [5, 6]. 
The formation of blood vessels involves two processes: 
angiogenesis which is the sprouting of new blood vessels 
from pre-existing ones, and vasculogenesis which is 
the recruitment of circulating endothelial progenitor 
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cells (EPCs) to form new blood vessels [7]. Moreover, 
bone marrow-derived VEGFR1-positive (VEGFR1+) 
hematopoietic progenitor cells (HPCs), in response to 
tumor-secreted growth factors and cytokines, may be 
recruited to distant organs to form clusters and create a 
permissive microenvironment that is structurally and 
functionally conducive to cancer metastasis [8, 9]. In 
addition, the progression from micro- to macro-metastasis 
depends on the establishment of functional vasculature, 
which involves the mobilization and recruitment of bone 
marrow-derived VEGFR2-positive (VEGFR2+) EPCs 
to the metastatic site [10, 11]. However, the paracrine 
effects of VEGFR1+ and VEGFR2+ BMDCs on cancer 
cells is unknown, and their contribution to human cancer 
pathogenesis remains to be further elucidated.
Esophageal squamous cell carcinoma (ESCC) is 
one of the most aggressive malignancies in the world and 
angiogenesis is a major clinical feature of aggressive ESCC 
[12, 13]. ESCC carries a very poor prognosis because many 
cases go undetected until the disease is at an advanced stage. 
Recent evidence indicates that the expression of VEGFR1 and 
VEGFR2 is correlated with prognosis of patients in various 
types of cancers [14–16]. However, little is known about the 
expression patterns and clinical significance of VEGFR1 
and VEGFR2 in ESCC. Whether blockade of VEGFR1 or 
VEGFR2 can inhibit progression of ESCC is still unknown.
Thus, in this study, we aim to investigate the 
significance of VEGFR1- and VEGFR2-expressing 
non-tumor cells including BMDCs, which constitute 
important components of the tumor microenvironment, in 
esophageal cancer progression, and to determine whether 
targeting these cells could suppress tumor angiogenesis 
and progression. The outcome of this study enhances our 
understanding of the functional significance of VEGFR1+/
VEGFR2+ non-tumor and tumor cells, which may serve as 
therapeutic targets in ESCC.
RESULTS
Targeting host VEGFR1 and VEGFR2 can 
suppress growth of human esophageal tumor 
xenograft in mice
To study the roles of VEGFR1- and VEGFR2-
expressing non-tumor cells in the development of 
esophageal cancer, we made use of mouse-specific 
antibodies to determine if blockade of host VEGFR1 and 
VEGFR2 had any effects on growth of xenografted human 
ESCC tumors in mouse models. Nude mice bearing 
subcutaneous human ESCC tumor xenografts derived 
from KYSE30 and KYSE270 cells were treated with anti-
mouse VEGFR1 and VEGFR2 neutralizing antibodies. 
The results showed that the antibodies MF-1 or DC101 
significantly suppressed tumor growth in human ESCC 
tumour xenografts in a dose-dependent manner. When 
a combination of MF-1 and DC101 was applied at low 
doses (10 mg/kg and 5 mg/kg respectively), improved 
tumor response was obtained compared to treatment 
with either one of the antibodies (Figure 1A). We also 
found that MF-1 and DC101, alone or in combination, 
could significantly reduce Ki-67-positive tumor cells 
in the KYSE30 and KYSE270 xenografts, suggesting 
that blockade of host VEGFR1/VEGFR2 could inhibit 
tumor cell proliferation (Figure 1B and Supplementary 
Figure S1A). Since the mouse-specific MF-1 and DC101 
antibodies exerted no significant inhibitory effect on 
proliferation of human ESCC cells in vitro (Supplementary 
Figure S2), the observed anti-tumor activity was unlikely 
to be a direct effect on human cancer cells but could 
be mediated by mouse non-tumor cells that expressed 
VEGFR1 or VEGFR2. To rule out the possibility of 
MF-1 and DC101 cross-reacting with human epidermal 
growth factor receptors (EGFR) expressed on cancer 
cells, the tumor xenografts were subjected to Western 
blot analysis of phosphorylation form of EGFR (p-EGFR) 
and EGFR. The results showed no significant difference 
in the expression of p-EGFR and EGFR between the 
treated and control groups (Supplementary Figure S3), 
thus confirming that the suppressive effects of MF-1 
and DC101 antibodies on tumor growth were not due to 
blockade of EGFR on cancer cells. In addition, we found 
that MF-1 and DC101 significantly decreased micro-
vessel density (MVD), as identified by CD31 (Figure 1C 
and Supplementary Figure S1B), which was indicative of 
repressed tumor angiogenesis. With the exception of the 
group treated with high dosage DC101, which showed a 
slight but statistically insignificant weight loss after two 
weeks, there was no obvious difference in body weight 
among the other groups (Supplementary Figure S4A). 
Histological evaluation of the vital organs of the mice, 
including lungs, liver and kidneys did not reveal overt 
changes in morphology (Supplementary Figure S4B), 
suggesting that the antibody treatments had no toxic 
effects.
Inhibitory effects of VEGFR1 and VEGFR2 
antibodies on tumor growth are partly attributed 
to anti-angiogenic influence
Decrease in tumor MVD in the MF-1 or DC101-
treated animals (Figure 1C and Supplementary Figure 
S1B) prompted us to further examine whether the anti-
tumor effects were due to inhibition of angiogenesis. 
We found that treatment with antibodies directed against 
human VEGFR1 and VEGFR2 (i.e. IMC-18F1 and IMC-
1121B, respectively) reduced the proliferation of VEGF-
stimulated HUVECs in a dose-dependent manner. Notably, 
a combination of both antibodies at low doses produced 
inhibitory effect comparable to high dose single-antibody 
treatments (Figure 2A). Moreover, the data from migration 
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Figure 1: Blockade of VEGFR1 and VEGFR2 suppressed growth of human ESCC xenografts in nude mice. (A) Growth 
curves of KYSE30 and KYSE270 tumor xenografts. (B) Immunohistochemical analysis of the Ki-67 proliferation index in KYSE30  
xenografts. (C) CD31-positive cells demonstrating micro-vessel density (MVD) in KYSE30 xenografts. Bars, SD; *, P < 0.05; **, P < 0.01, ***,  
P < 0.001 compared with isotype IgG-treated mice.
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Figure 2: Blockade of VEGFR1 and VEGFR2 inhibited VEGF-induced angiogenesis in vitro and in vivo. (A–C) The 
proliferation (A), migration (B), tube formation (C) of human umbilical vein endothelial cells (HUVECs) were evaluated after treatment 
with IMC-18F1, IMC-1121B alone or in combination, in the presence or absence of recombinant VEGF. (D) Lysates from HUVECs 
were collected for Western blot analysis of p-VEGFR1 (Tyr1213), p-VEGFR2 (Tyr1175), VEGFR1, VEGFR2, p-Erk (Thr202/Tyr204), 
p-Src (Tyr416), Erk and Src. (E) Matrigel plug assay was performed to assess the anti-angiogenic effect of MF-1 and DC101 in vivo. The 
hemoglobin (Hb) content in the matrigel plugs was measured and expressed relative to that of isotype control without VEGF treatment. 
(F) Determination of CD31 MVD in the excised matrigel plugs. Bars, SD; *, P < 0.05; **, P < 0.01, ***, P < 0.001 compared with the cells 
or mice treated with VEGF and isotype IgG.
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chamber assay showed that IMC-18F1 or IMC-1121B 
used alone at higher doses, or in combination with each 
other at low doses, abolished VEGF-stimulated migration 
of HUVECs (Figure 2B). Our results also showed that 
blockade of VEGFR1 and/or VEGFR2 significantly 
and dose-dependently decreased tube formation ability 
of HUVECs under VEGF stimulation (Figure 2C and 
Supplementary Figure S5A). Western blot analysis showed 
that VEGF upregulated the expression of p-VEGFR1, 
p-VEGFR2, p-Src and p-ERK in HUVECs, and that 
VEGFR1 and VEGFR2 antibodies attenuated these effects 
(Figure 2D).
In vivo matrigel plug assay was performed to assess 
anti-angiogenic effect upon blockade of host VEGFR1 
and VEGFR2. The results showed that MF-1 and/or 
DC101 inhibited VEGF-induced neovascularization 
in tumor cell-free matrigel plugs (i.e. in the absence of 
paracrine influence from tumor cells), as evidenced by the 
significantly lower hemoglobin content (Figure 2E) and 
decreased MVD (Figure 2F and Supplementary Figure 
S5B) in the matrigel plugs. These data confirm that the 
tumor-suppressive effects of MF-1 and DC101 were due, 
at least in part, to inhibition of angiogenesis.
Targeting host VEGFR1 and VEGFR2 results 
in a reduction of VEGFR1+ hematopoietic 
progenitor cells and VEGFR2+ endothelial 
progenitor cells
Although VEGFRs are normally found on vascular 
endothelial cells, bone marrow progenitor cells which 
express VEGFR1 and VEGFR2 have been reported to play 
an important role in the development of cancer. The success 
of MF-1/DC101 treatment in retarding tumor growth led us 
to explore whether bone marrow-derived VEGFR1+ HPCs 
and VEGFR2+ EPCs cells were involved in mediating these 
effects. Flow cytometric analysis of single-cell suspensions 
of tumor xenografts showed that treatment with MF-1 and 
DC101 led to dose-dependent decrease in the number 
of host VEGFR1+ and VEGFR2+ cells respectively 
(Figure 3A–3B). Notably, we also observed a dose-
dependent decrease of VEGFR1+ and VEGFR2+ cells in 
the bone marrow of treated mice (Figure 3C–3D).
VEGFR-immunoneutralization inhibits VEGF-
stimulated proliferation and migration of VEGFR1+ 
and VEGFR2+ bone marrow-derived cells
It was reported that VEGFR1+ and VEGFR2+ 
BMDCs contribute to tumor angiogenesis and 
progression. Such function is likely dependent on 
increased proliferation and migration of these cells so 
as to facilitate their recruitment into developing tumors 
as well as metastatic sites during cancer progression. 
There is as yet no report on the direct effects of VEGFR 
blockade on BMDCs. We sorted VEGFR1+ and 
VEGFR2+ bone marrow cells from mouse bone marrow 
(Supplementary Figure S6) for ex vivo culture, and 
studied the effects of VEGF stimulation and VEGFR-
immunoneutralization on cell proliferation and migration. 
The data showed that treatment with MF-1 and DC101 
significantly attenuated VEGF-stimulated proliferation of 
VEGFR1+ and VEGFR2+ bone marrow cells, respectively 
(Figure 4A–4B). The results from migration chamber 
assay showed that the antibodies suppressed the 
chemotaxis of corresponding VEGFR1+ and VEGFR2+ 
bone marrow cells in response to VEGF (Figure 4C–4D). 
Western blot analysis showed that MF-1 and DC101 
abolished VEGF-induced phosphorylation of VEGFR1 
and VEGFR2, respectively, in sorted VEGFR1+ and 
VEGFR2+ bone marrow cells. In addition, our results 
showed that VEGF increased the expressions of p-Src and 
p-Erk in these cells, and that the effects were abrogated by 
blockade of VEGFR1 and VEGFR2 (Figure 4E), which 
were consistent with the effects on HUVECs (Figure 2D).
Blockade of VEGFR1 and VEGFR2 in human 
umbilical vein endothelial cells and bone 
marrow-derived cells reduces their pro-invasive 
effect on cancer cells
Next we explored the significance of VEGFR1/
VEGFR2 pathways in the interactions between cancer 
cells and endothelial cells as well as bone marrow cells 
in the tumor microenvironment. Invasion assay showed 
that the conditioned medium (CM) from VEGF-pretreated 
HUVECs could increase the invasive ability of ESCC 
cells and that the effect was abrogated in the presence 
of VEGFR1/VEGFR2 antibodies (Figure 5A–5B). In 
addition, to mimic the metastatic microenvironment in 
which BMDCs might exert paracrine influence on cancer 
cells, CM was collected from VEGF-stimulated VEGFR1+ 
and VEGFR2+ bone marrow cells for invasion chamber 
assay (Figure 5C). The results showed enhanced invasion 
of human ESCC cells within 24 h, and that blocking 
VEGFR1 on bone marrow cells with MF-1, or VEGFR2 
with DC101, partially abolished this effect (Figure 5D). 
These data collectively indicate that VEGFR1+/VEGFR2+ 
endothelial and BMDCs play a vital role in the chemo-
attraction of circulating cancer cells, and that blockade 
of VEGFR1/VEGFR2 could significantly prohibit this 
process.
Blockade of host VEGFR1 and VEGFR2 reduces 
cancer metastasis
In light of the pro-invasive effect of HUVECs and 
BMDCs on cancer cells, we next determined whether 
blockade of host VEGFR1 and VEGFR2 could inhibit 
cancer metastasis. Using bioluminescence imaging in an 
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experimental metastasis model, we found that treatment 
with MF-1 and/or DC101 significantly decreased the 
colonization of intravenously injected ESCC cells to the 
lungs, compared with control animals receiving isotype 
IgG (Figure 6A). This finding was confirmed by the 
reduction in expression of human-specific cytokeratin 
8 protein which identified the human cancer cells 
(Figure 6B), and in the extent of macro-metastases in the 
lungs of the treatment groups (Figure 6C). In addition, 
we found that the MF-1 and DC101-treated groups had 
significantly lower percentage of VEGFR1+ and VEGFR2+ 
cells respectively in the lungs (Figure 6D). Furthermore, 
treatment with the antibodies was found to improve the 
survival rates of the mice (Figure 6E). Taken together, 
these data demonstrate that host VEGFR1+ and VEGFR2+ 
cells play an important role in metastasis, and that 
targeting these cells using neutralization antibodies can 
decrease distant metastases in ESCC.
Clinical significance of VEGFR1 and VEGFR2 
in ESCC
Although our results showed that targeting host 
VEGFR1+ and VEGFR2+ non-tumor cells was sufficient 
to inhibit tumor growth, the notion that a therapy may be 
more effective if it can target both the cancer cells and 
its microenvironment prompted us to investigate the 
expression patterns and clinical significance of VEGFR1 
and VEGFR2 in ESCC. Two of the 22 cases in the first 
TMA were excluded because the cancer-adjacent tissue 
sections did not contain esophageal epithelium. Of the 
remaining 20 cases of ESCC, 45% (9/20) and 35% (7/20) 
expressed higher VEGFR1 and VEGFR2, respectively, 
in the cytoplasm of cancer cells compared with cancer-
adjacent normal esophageal epithelium (Figure 7A–7B).
To evaluate the clinicopathological impact and 
prognostic significance of VEGFR1 and VEGFR2 
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Figure 3: Flow cytometric analysis of percentage of VEGFR1+ and VEGFR2+ cells in tumor xenografts and bone 
marrow. (A–D) Treatment with MF-1 and DC101 reduced the number of VEGFR1+ and VEGFR2+ cells, respectively, in tumor xenografts 
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expressions, another tissue array containing 86 cases of 
ESCC collected prospectively by our group was used. 
High expression of VEGFR1 and VEGFR2 was found 
in 59% (51/86) and 28% (24/86) cases, respectively 
(Figure 7C–7D). Overall, 45/86 (52%) of the cases shared 
the same level of expression for both receptors, i.e. high 
expression of both VEGFR1 and high VEGFR2 (17 cases), 
or low expression of both VEGFR1 and VEGFR2 (28 
cases). Furthermore, VEGFR1 expression was noted to be 
significantly correlated with the TMN pathological staging 
whereas VEGFR2 expression was associated with the 
presence of metastases (M stage) of the cancer (Table 1). 
The survival of the patients with ESCC was found to 
be associated with the pathological stages (P = 0.031) 
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Figure 5: The pro-invasive effect of HUVECs or bone marrow cells on cancer cells. (A, B) Invasion chamber assay was 
used to evaluate the invasion of KYSE270 cells attracted by HUVECs in the presence or absence of IMC-18F1 and IMC-1121B. (C, D) 
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(Figure 7E). Other than these, there was no significant 
association with other clinical and pathological parameters 
including age, gender of the patients, tumor site, and tumor 
grade (Table 1).
Roles of VEGFR1 and VEGFR2 expressions in 
cancer cell lines
We also compared a panel of ESCC cell lines and 
non-cancer esophageal epithelial cell lines for VEGFR1 
and VEGFR2 expressions, and found that the majority 
of cancer cell lines expressed higher VEGFR1 and 
VEGFR2 compared with non-cancer esophageal epithelial 
cells (Figure 7F). Two ESCC cell lines with relative 
high expression of VEGFR1 and VEGFR2 were treated 
with VEGFR1 and VEGFR2 antibodies, and the results 
showed that proliferation of the treated cancer cells 
was significantly inhibited by the antibody treatments 
(Figure 7G), which suggests that ESCC cells are also valid 
targets for VEGFR1/VEGFR2 antibody therapies.
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DISCUSSION
In recent years, the role of BMDCs in development 
of cancer and their dialogue with cancer cells are under 
intensive investigation. Controversy exists as to whether 
BMDCs in the tumor microenvironment possess tumor-
promoting or anti-tumor activities [17–19]. This may be 
partly explained by the complexity of their interaction 
with tumor cells. Although there are a number of reports 
documenting the recruitment of VEGFR1+ HPCs and 
VEGFR2+ EPCs to tumor and metastatic sites which 
facilitates cancer progression in murine models [11, 20], 
direct evidence of VEGFR1+ and VEGFR2+ BMDCs 
having paracrine effects on cancer cells is still lacking and 
the molecular pathways underlying their functions remain 
undefined. In this study, we showed for the first time that 
VEGF-induced bone marrow cells could instigate the 
mobility of cancer cells.
Although the activation of Src and Erk pathways are 
crucial players in oncogenesis through mediating multiple 
signaling pathways [21, 22], most studies investigated their 
functions in cancer cells. Little is known about their roles 
Table 1: Correlation between VEGFR1 or VEGFR2 expressions and clinicopathological 
characteristics of 86 cases of ESCC
Parameters
VEGFR1 VEGFR2
Low High Total P value Low High Total P value
Number 35 51 86 - 62 24 86 -
Mean age 61 65 - 0.067 62 64 - 0.32
Mean diameter 5.4 5.2 - 0.643 5.5 4.9 - 0.27
Gender
Male 29 45 74 51 23 74
Female 6 6 12 0.577 11 1 12 0.166
Differentiation
Well and moderate 30 41 71 50 21 71
Poor 5 10 15 0.577 12 3 15 0.542
Location
Upper or middle 25 29 54 40 14 54
Lower 10 22 32 0.183 22 10 32 0.626
T-Stage
1/2 3 1 4 48 17 65
3/4 32 50 82 0.3 14 7 21 0.58
N-Stage
N0 11 11 22 18 4 22
N1 24 40 64 0.325 44 20 64 0.283
M-Stage
M0 34 50 84 62 22 84
M1 1 1 2 1 0 2 2 0.022
Stage
1 1 1 2 1 1 2
2 10 6 16 14 2 16
3 23 43 66 47 19 66
4 1 1 2 0.049 0 2 2 0.051
Abbreviations: T, tumor; N, nodal; M, metastasis
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in bone marrow cells. In this study, we found that VEGF 
could activate the Src and Erk pathways in VEGFR1+ and 
VEGFR2+ BMDCs, and that blockade using corresponding 
VEGFR antibodies not only attenuated this effect, but also 
abolished the VEGF-induced proliferation and migration 
of sorted VEGFR1+ and VEGFR2+ BMDCs. The results 
suggest that activation of the Src and Erk pathways may 
contribute to the functions of VEGFR1+ and VEGFR2+ 
BMDCs in promoting cancer progression.
Cancer cells have long been regarded as the 
exclusive target in cancer therapy, but recent studies 
suggest that novel approaches that disrupt the tumor-
host interactions may complement standard treatments to 
improve treatment efficacy [23]. A better understanding of 
the interactions between cancer cells and their local and 
systemic environments is therefore essential. Angiogenesis 
is the most obvious evidence of the tumor stroma playing 
a supportive role in tumor development, and targeting 
tumor angiogenesis has emerged as a promising anti-
tumor strategy [24–26]. Since the introduction of the first 
effective therapeutic antibodies in cancer treatment (i.e. 
rituximab and trastuzumab), there has been an explosion 
of therapeutic antibodies. Till now, around 13 antibodies 
have been approved by the FDA as cancer drugs and many 
more are currently being evaluated in clinical trials [27]. 
These antibodies are currently used in the treatment of 
metastatic cancer such as colorectal cancer and breast 
cancer with good therapeutic responses. Compared with 
the small-molecule agents, antibody therapy generally has 
advantages such as longer duration of action and less inter-
patient variability at a given dose from the perspective of 
pharmacokinetic studies [28]. In this study, we showed 
that blockade of host VEGFR1 or VEGFR2 by using the 
species-specific neutralizing antibodies could suppress 
ESCC tumor growth, angiogenesis and metastasis in 
preclinical models, thus providing strong evidence of the 
importance of tumor micro- and systemic environments in 
cancer progression.
It is widely accepted that VEGFR2 mediates 
most of the cellular responses to VEGF [29], while the 
downstream signaling of VEGFR1 is less well defined. 
Our results showed that simultaneous blockade VEGFR1 
and VEGFR2 had co-adjuvant inhibitory effect on tumor 
growth and metastasis. This concurs with the notion that, 
due to the complexity of angiogenesis, multiple-targeting 
may be beneficial in the treatment of tumor angiogenesis 
and metastasis [30]. The remarkable anticancer effects and 
low toxicity of monoclonal antibodies in our preclinical 
models suggest that VEGFR1 and VEGFR2 antibodies 
could have a clinical role in treatment of ESCC.
Information on the clinicopathological significance 
of VEGFR1 and VEGFR2 in ESCC is scarce. Compared 
to earlier immunohistochemical studies of VEGFR1 
and VEGFR2 expressions in human ESCC [31, 32], 
ours was conducted on the largest patient cohort. Our 
data showed that the expressions of both receptors were 
correlated with the pathological stages of the ESCC. Thus, 
targeting these receptors in metastasizing ESCC may be 
useful in the treatment of the disease. It is noteworthy 
that approximately one fifth of the ESCC showed high 
expression of both VEGFR1 and VEGFR2, which further 
emphasizes the merit of targeting both VEGFR1 and 
VEGRF2 in the treatment of ESCC. Our data collectively 
demonstrated for the first time the clinicopathological 
significance of VEGFR1 and VEGFR2 in ESCC and their 
potential to be druggable targets for this deadly disease. 
More importantly, the inhibitory effect of anti-human 
VEGFR antibodies on the human cancer cell proliferation 
(Figure 7G) corroborate that better tumor response may 
be obtained using therapeutic agents which are capable of 
targeting both the cancer microenvironment and the cancer 
cells. IMC-1121B (also known as Ramucirumab) was 
recently approved by FDA in April 2014 as second-line 
therapy for patients with gastric cancer.
In conclusion, our study demonstrated that 
VEGFR1+ HPCs and VEGFR2+ EPCs play significant 
functional roles in tumor progression, and that targeting 
the host non-tumor VEGFR- expressing cells could inhibit 
tumor growth, angiogenesis and metastasis. The cellular 
and molecular mechanisms of how cancer cells instigate 
the recruitment and mobilization of VEGFR1+ and 
VEGFR2+ BMDCs to developing tumors and to metastatic 
sites warrant further study.
MATERIALS AND METHODS
Cell lines
The cell lines recruited in this study included 
human ESCC cells, endothelial cells and immortalized 
esophageal epithelial cells. Human ESCC cell lines 
KYSE30, KYSE150, KYSE270, KYSE410, KYSE510, 
KYSE520 (DSMZ, Braunschweig, Germany) [33], as well 
as HKESC-1 [34] and HKESC-2 [35], were maintained 
in RPMI 1640 (Sigma, St Louis, MO) supplemented with 
10% fetal bovine serum (Invitrogen, Gaithersburg, MD). 
Human umbilical vein endothelial cells (HUVECs) obtained 
from Invitrogen were cultured in M200/LSGS medium 
(Invitrogen). Human immortalized normal esophageal 
epithelial cell lines NE2-hTERT [36] and NE083-hTERT 
[37] were maintained in defined K-SFM (Invitrogen).
Antibodies for immunoneutralization
Species-specific, non-cross-reactive monoclonal 
antibodies targeting mouse VEGFR1 (MF-1) and mouse 
VEGFR2 (DC101), as well as fully human monoclonal 
antibodies directed against human VEGFR1 (IMC-18F1) 
and human VEGFR2 (IMC-1121B), were provided by 
ImClone Systems (New York, NY) [38–41].
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In vivo tumorigenesis experiments
In vivo tumorgenesis and metastasis experiments 
were described previously [42, 43]. All animal care and 
experimental procedures were approved by the Committee 
on the Use of Live Animals in Teaching and Research, 
University of Hong Kong. Briefly, 1 × 106 KYSE30 or 
5 × 105 KYSE270 cells suspended in a 1:1 mixture of 
phosphate buffered saline/Matrigel were subcutaneously 
injected into the flank of nude mice. When the tumors 
reached ~5 mm diameter, the mice were randomized 
into different groups then treated with indicated doses 
of neutralizing antibodies specific for mouse VEGFR1 
(MF1) and VEGFR2 (DC101) intraperitoneally thrice 
weekly (n = 6 per group). During the experiment, the 
tumor volume and body weight were measured every 
3 days. Tumor volumes were calculated with the equation 
V = (length × width2)/2. At the end of the experiments, 
the tumors, lungs, liver, and kidneys of the animals were 
collected for further analysis. Immunohistochemical 
analysis of proliferative index and MVD was performed 
using antibodies against Ki-67 (Dako, Mississauga, ON, 
Canada) and CD31 (Santa Cruz Biotechnology, Santa 
Cruz, CA), respectively.
In vivo experimental metastasis experiments
In brief, 1 × 106 luciferase-expressing KYSE150 
cells (KYSE150-Luc) were injected intravenously into the 
systemic circulation of nude mice via the tail vein (n = 9 
per group). After 7 days, the mice were treated with MF1 
and/or DC101 every 3 days. Metastasis was monitored by 
bioluminescent imaging.
In vivo matrigel plug assay
Matrigel plug assay was performed according 
to the method described by Passaniti et al [44]. See 
supplementary materials and methods for details.
Preparation of cell suspensions from mouse bone 
marrow, tumor xenografts and lungs
See supplementary materials and methods for 
details.
Fluorescence-activated cell sorting and analysis
Bone marrow cells, as well as cell suspensions 
of lungs and tumor xenografts were labeled with 
phycoerythrin-conjugated anti-mouse VEGFR1 (#141522, 
R&D Systems, Minneapolis, MN), anti-mouse VEGFR2 
(#Avas12a1, eBioscience Inc., CA) or with corresponding 
isotype control antibody. See supplementary materials and 
methods for details.
Western blot analysis and cell proliferation, 
migration, invasion assays
Western blot analysis, cell proliferation, migration 
and invasion assays were performed as previously 
described [45, 46]. Please see the supplementary materials 
and methods for details.
Endothelial tube formation assay
The tube formation assay was performed according 
to Bae et al. [47]. Please see the supplementary materials 
and methods for details.
Tissue microarray analysis
A human esophageal cancer tissue microarray 
(TMA) containing 22 cases of ESCC with cancer-
adjacent normal esophageal tissue (ES722, Biomax, 
Rockville, MD), as well as another TMA containing 
86 cases of primary ESCC were used to investigate the 
expression of VEGFR1 and VEGFR2. The latter TMA 
was constructed from ESCC of 86 patients who had 
undergone esophagectomy between 1991 and 1998 at 
the Department of Surgery, University of Hong Kong 
Medical Centre, Queen Mary Hospital, Hong Kong. None 
of these patients had received neo-adjuvant chemotherapy 
or radiotherapy. Immunohistochemical approach was 
taken to detect the expression of VEGFR1 and VEGFR2 
using anti-VEGFR1 (#AF321, R&D Systems) and anti-
VEGFR2 (#2479, Cell Signaling Technology, Beverly, 
MA) antibodies respectively. The immunohistochemical 
staining for VEGFR1 and VEGFR2 expressions was 
classified into four categories: no or negligible staining 
(score 0), weakly positive with less than 10% tumor cells 
(or esophageal epithelial cells for sections of cancer-
adjacent tissue) stained (score +), moderate intensity with 
10 to 30% cells stained (score ++), and strong staining 
intensity in > 50% cells (score +++). Cases with scores 
of 0, + or ++ were grouped as “low” expression, whereas 
those with a score of +++ were regarded as having high 
expression.
Statistical analysis
All in vitro experiments and assays were repeated at 
least 3 times, and the data were expressed as mean ± SD 
and compared by ANOVA. For the TMA results, the data 
were entered into a computer database and the statistical 
analysis was performed using SPSS for Windows (version 
22.0, IBM SPSS Inc., New York, NY). For continuous 
variables, analysis was done using Student’s t-test and 
one-way ANOVA to determine if there was a significant 
difference in expression of the receptors between tissue 
groups. Fisher’s exact test or likelihood ratio was used 
for analyzing the association between expression level of 
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receptors and categorical clinicopathological variables. 
Survival analysis was performed by Kaplan-Meier method 
with the log-rank test. P values < 0.05 were considered as 
significant for all experiments.
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